Talha Badar: CRh as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia

Talha Badar shared on X:

“Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia

Pooled analysis of IDH1/2i and FLT3i in clinical trails, suggest CRh meaningful endpoint in improving outcome with non-myelosuppressive therapies.

Authors: Robert Q. Le, Donna Przepiorka, Haiyan Chen, Yuan Li Shen, E. Dianne Pulte, Kelly Norsworthy, Marc R. Theoret, R. Angelo De Claro.”

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.